NCT05648019View on ClinicalTrials.gov

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Lymphoblastic LeukemiaLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute AdultB-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaCAR
Interventions
BIOLOGICAL

Anti-CD19 CAR T-cells

A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.

Trial Locations (2)

169608

RECRUITING

Singapore General Hospital, Singapore

229899

RECRUITING

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
collaborator

Singapore General Hospital

OTHER

lead

KK Women's and Children's Hospital

OTHER_GOV